Introduction
Autosomal recessive polycystic kidney disease (ARPKD) (MIM 263200) has an estimated incidence of 1:20 000 and belongs to a group of congenital hepatorenal fibrocystic syndromes [1] [2] [3] [4] . Despite a considerably broad spectrum of symptoms, fusiform dilation of the renal collecting ducts and distal tubules as well as dysgenesis of the hepatic portal triad (ductal plate malformation) are invariable histological manifestations of the disease [4] . Approximately 50% of patients suffer from end-stage renal disease already at 10 years of age, and with the current therapy for renal and/or hepatic, disease is symptomatic only [5] . ARPKD is caused by mutations in the PKHD1 gene (6p12) encoding a large multi-domain integral membrane protein (fibrocystin/polyductin, FPC) [6] [7] [8] . Although the function of FPC is still largely unknown, in vitro experi-ments point to a role in signal transduction, and nuclear translocation of the C-terminal fragment has been shown [9] [10] [11] . Beyond this, FPC and the autosomal dominant polycystic kidney disease (ADPKD) proteins, polycystin-1 and polycystin-2 (PC-1 and PC-2), do not only colocalize to the primary cilium but also show functionally a relevant interaction [3, 8, [12] [13] [14] [15] [16] . This might explain why ARPKD and ADPKD, apart from all clinical and genetic differences, are rather similar and has lead to the 'ciliary hypothesis' for PKD [17] [18] [19] .
Whereas symptomatic treatment is still only available to ARPKD patients, the improved understanding of signal transduction pathways and cellular changes associated with ADPKD have been translated into clinical trials (for review see [3] and references cited therein). In particular, constitutive activation of the mTOR pathway has been shown in three rodent models of ADPKD, and targeted inhibition of mTOR was able to improve renal function while decreasing cyst growth and kidney size [20, 21] . Furthermore, in transplanted ADPKD patients receiving rapamycin as immunosuppressive therapy, shrinking of the native kidneys and/or liver was noticed [22, 23] . Accordingly, targeted inhibition of mTOR most likely has the potential to attenuate progression of disease in ADPKD, and this hypothesis is currently evaluated in several prospective clinical trials [22, [24] [25] [26] . Recently, we have obtained evidence that the mTOR pathway is activated in kidneys derived from children with ARPKD as well [27] . This observation together with the known interaction of PFC, PC-1 and PC-2 has lead us to investigate sirolimus as a therapeutic tool in PCK rats, i.e. an orthologous model of human ARPKD [28] [29] [30] [31] . These animals closely resemble the phenotype of human disease, and show polycystic kidney and liver disease already at young age.
Materials and methods

Animals
PCK rats were obtained from a breeding colony housed at the Medical Faculty of Mannheim, Germany. The colony was established in 2004 from a litter that was obtained from X. Wang and V. E. Torres (Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN, USA). PCK rats harboured a splicing mutation (IVS35-2A → T) with a subsequent skipping of exon 36 and a frame shift in the orthologue Pkhd1, making them an excellent model of human ARPKD [8, 32] .
Weaned Sprague-Dawley (Crl:CD) rats (3-4 weeks of age; 36 male and 36 female) were purchased from Charles River Laboratories, Sulzfeld, Germany. All animal handling and experiments outlined in this study were in accordance with the accepted principles of the welfare of animals used in science and were approved by the regulatory authority. The rats had free access to water and standard rat chow (V1534, Ssniff, Soest, Germany) throughout the study.
Study drug
Sirolimus (Rapamune ™ oral solution; 1 mg/mL, Wyeth Pharma GmbH, Muenster, Germany) was used. The drug was administered via the drinking water without further additives [21] .
Experimental protocol
PCK rats (34 male and 51 female derived from 11 litters) were weaned at 4 weeks of age, and PCK as well as SD rats were housed pairwise according to gender, strain and therapy group (Table 1) . Animals were randomly assigned to therapy with sirolimus (2 mg/kg body weight per day) or to serve as untreated controls. Sirolimus (1 mg/mL) was administered via the drinking water for either 4, 8 or 12 weeks, respectively. The number of rats per group is given in Table 1 . Black drinking bottles (Tecniplast, Hohenpeißenberg, Germany) were used to assure light protection, and dosages were adjusted to body weight and daily fluid intake twice weekly. The drug solution was freshly prepared every morning. Rats were housed in metabolic cages before onset of therapy, at half of the observation period and at the end of the observation period. Blood was drawn from the tail veins before onset of therapy and at half of the observation period, and was collected by cardiac puncture at the end of the experiment. Blood was collected in EDTA-coated tubes (determination of sirolimus) and plastic serum separator tubes (Sarstedt, Nümbrecht, Germany), respectively. The latter were allowed to clot at room temperature, centrifuged (2000 g, 15 min), aliquotted and stored at −80°C until further analysis. Systolic BP was determined at half of the treatment periods by tail-cuff using a sphygmomanometer (TSE systems, Bad Homburg, Germany). For labelling of proliferating cells, bromodeoxyuridine (BrdU) was delivered via the drinking water (BrdU: 1 g/L and glucose: 10 g/L) during a 10-day period preceding the end of the experiment. At the end of the treatment periods, rats were sacrificed under ketamine/xylazine (80 and 16 mg/kg, respectively) anaesthesia. Kidneys and liver were removed and weighed. Slices of both organs were preserved in 4% paraformaldehyde and embedded in paraffin for histological examination.
Blood chemistry
Serum BUN, creatinine, liver enzymes, bilirubin and bile acids as well as urinary creatinine and protein were determined by utilization of kinetic colour tests (Diasys Diagnostic Systems/Greiner Biochemica, Flacht, Germany). Tests were performed manually and adapted to microtitre plate format, and all samples were assayed in duplicate. Sirolimus was determined by means of HPLC-mass spectroscopy at half of the observation period and at time of sacrifice (Institute of Toxicology, Clinical Toxicology and Berlin Poison Information Centre, Berlin, Germany).
Histomorphometric analysis
Liver sections and whole transverse kidney tissue sections (5 μm) were stained with Masson-Goldner trichrome stain and picosirius red to measure cyst area and fibrosis, respectively [33] . Images from MassonGoldner-stained kidney sections were taken at low magnification (macrosettings) with a digital camera (Olympus SP-550 UZ). Slides were viewed with a microscope (Leica DMI 4000, Leica, Wetzlar, Germany) equipped with digital cameras [DFC 320 R2 (colour) and DFC 350 Fx (black and white); Leica, Wetzlar, Germany] and corresponding software (Leica Application Suite, LAF6000, Wetzlar, Germany) for data acquisition. The QWin software package (Leica Microsystems, Wetzlar, Germany) was used for an interactive quantitative image analysis. While the entire kidney section was submitted to quantitative image analysis, four highpower field images were taken per liver section. Cysts and non-cystic tissue were discriminated by colour. Relative cyst area was calculated Numbers of animals intended to treat are given in brackets. Animals which died during the observation periods were not included, as organs and blood were not harvested.
a Rats that had to be sacrificed before onset of therapy.
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as the ratio of total cyst area to tissue section area, essentially as described [34, 35] . Picosirius red-stained sections were examined by fluorescence microscopy using settings for fluorescein isothiocyanate (FITC). Under this condition, collagen fibres appeared red-orange. Discrimination between fibrotic and non-fibrotic areas was improved manually, and the relative fibrotic area was calculated as the ratio of total fibrotic area to tissue section area.
Immunohistochemistry
Immunohistochemical analysis was performed essentially as described recently [27] . Polyclonal antisera specific for the rat-specific isoforms of Thr-308 phosphorylated Akt (sc-16646-R; Santa Cruz Biotechnology Inc, Heidelberg, Germany), Ser-2448 phosphorylated mTOR (ab51044; abcam, Cambridge, UK) and Thr-389 phosphorylated S6K (sc-11759; Santa Cruz Biotechnology Inc, Heidelberg, Germany) were used. BrdUlabelled cells were detected by means of a mouse monoclonal antibody (clone Bu20a, M 0744; DakoCytomation, Denmark). Endogenous biotin was blocked to reduce background staining (Avidine/Biotin blocking kit, Vector Laboratories, Inc., Burlingame, CA, USA). Biotin-conjugated secondary antibodies (donkey anti-goat IgG, donkey anti-mouse IgG and goat anti rabbit IgG; all from Dianova, Hamburg, Germany) showing minimal cross-reactivity to rat proteins were used throughout the study. For negative controls, the specific antibody was replaced by an unrelated antibody of the same subclass (isotype control).
Statistical analysis
Data were analysed using the SPSS statistical package 15.0 (SPSS Inc. Chicago, IL, USA). Descriptive statistics including mean and standard deviation (SD) for continuous variables were computed. The KolmogorovSmirnov test was applied to assess normal distribution. Differences in continuous variables between treated and non-treated rats or between PCK and SD rats from corresponding groups were investigated using the t-test for independent samples or the Mann-Whitney rank test, as appropriate. All P-values resulted from two-sided statistical tests, and P < 0.05 was considered to be significant.
Results
In general, PCK rats tended to be smaller than SD rats despite a comparable daily food intake. The mean systolic blood pressure tended to be slightly elevated in PCK rats compared with SD rats, albeit the differences were not significant (data not shown). Up to the age of 16 weeks, kidney function, as judged from serum creatinine and serum urea, was fairly comparable between PCK and SD rats, whereas PCK rats showed significant proteinuria (each P < 0.05; Table 2 ). Two SD rats had to be euthanized for reasons not related to the study before onset of therapy. None of the SD rats receiving either vehicle or sirolimus died during the study period. Likewise, vehicletreated PCK rats (n = 39) survived throughout the respective study periods, whereas five out of 46 PCK rats receiving sirolimus died after being treated for 2 weeks (one male), 3 weeks (one male) and 6 weeks (two females and one male), respectively (P < 0.05; sirolimus versus vehicle). All of these animals showed unspecific signs of illness, i.e. loss of weight and apathy, during 1 or 2 days before death. After treatment for 4, 8 and 12 weeks, mean blood concentrations of sirolimus were 0.61 ± 0.06, 0.61 ± 0.05 and 0.64 ± 0.09 ng/mL in PCK rats, and 0.52 ± 0.02, 0.54 ± 0.02 and 0.59 ± 0.09 ng/mL in SD rats, respectively (for each time point, PCK rats versus SD rats P > 0.05). Body weight at the end of the treatment periods was slightly reduced in PCK and SD rats receiving sirolimus compared with controls (Table 2) .
Macroscopic examination at time of sacrifice revealed grossly enlarged kidneys and livers in PCK rats, whereas other organs like the heart and lungs were quite comparable not only between PCK and SD rats but also between treated and non-treated animals. Hepatic fibrosis together with enlarged bile ducts was readily detectable in PCK rats. Relative kidney and liver weights were significantly increased in PCK rats compared with SD rats, irrespectively of treatment (Tables 2 and 3 ; Figure 1 ). Furthermore, in SD rats, the relative weight of liver and kidney significantly decreased with ageing (Tables 2 and 3 ). Male PCK rats showed a significantly reduced relative kidney weight after 12 weeks of treatment, and a similar tendency, albeit not significant, was seen in female PCK rats. The relative liver weights, as well as cyst area and fibrosis in kidneys and liver, progressed apparently independent of sirolimus therapy. Whereas the number of proliferating cells, i.e. the ones being labelled with BrdU during the 10 days before sacrifice, was declining in SD rats, it remained comparably high and even unrelated to treatment in PCK rats (Table 3 ). In line with this, sirolimus-treated PCK rats showed only a minor inhibition of renal mTORspecific phosphorylation of S6K (Figure 2 ). Despite the almost complete absence of beneficial therapeutic effects, a tremendous increase of conjugated serum bilirubin and bile acids was noted in treated male but not in female PCK rats (Figure 3 ; Table 3 ). This effect was virtually absent in sirolimus-treated SD rats. 
Discussion
Numerous pathways related to cell growth and proliferation impinge on mTOR, and aberrant activation of mTOR was shown in several malignant and benign proliferation disorders including ADPKD [20, 21, 24, [36] [37] [38] [39] [40] [41] . Inhibition of mTOR by means of rapamycin and derivates thereof has been demonstrated to be effective in several rodent models of ADPKD and is currently under investigation in clinical trials [3, 20, 21, 23] . Recently, we have obtained evidence that AKT/mTOR signalling is activated in renal tissue of children with clinically and genetically proven ARPKD [27] . This finding, together with the known interaction of FPC with PC-1 and PC-2, the proteins mutated in ADPKD, led us to hypothesize that inhibition of mTOR might be a treatment option in ARPKD as well. To elucidate our hypothesis, we investigated the time-dependent effects of sirolimus in PCK rats, an orthologous animal model of human ARPKD. Similar to humans, these animals present with both hepatic disease due to a malformation of the bile ducts and polycystic kidneys [28] [29] [30] .
However, the hepatic phenotype is much more prominent in PCK rats, as judged from macroscopic evaluation at time of sacrifice and supported by elevated serum levels of bilirubin and bile acids. In contrast, despite enlarged polycystic kidneys, renal function with respect to serum creatinine and urea appeared to be rather well preserved, although proteinuria was remarkable. Although 12 weeks of continuous sirolimus therapy was sufficient to reduce the relative kidney weight in male PCK rats, cyst growth and/or progression of fibrosis were not attenuated. Furthermore, serum concentrations of urea and creatinine tended even to be higher in treated male PCK rats compared with controls, whereas in female PCK rats, no effects at all were seen.
It has to be emphasized that, despite being an orthologous model of human ARPKD and a renal phenotype with multiple cysts and fibrosis, renal function is only mildly impaired in PCK rats. Therefore, it might be questioned if PCK rats are really appropriate to study kidney-specific treatment effects. In contrast, liver disease was most prominent and readily detectable. Regardless of that, our treat- ment approach was systemic rather than organ-specific, and thus was expected to impact on the liver function as well. Again, virtually, no beneficial effects but a strong tendency for aggravation of liver disease in male PCK rats was observed. In line with this, five out of 46 PCK rats receiving sirolimus died during the experiment. Although these animals presented with rather unspecific signs of illness 1 or 2 days before decay, the intensity of these symptoms did not justify the pre-emptive sacrifice as transient loss of appetite with spontaneous recovery after 2-3 days was occasionally seen throughout the study. Most probably, liver function was severely impaired in these animals, and thus, tolerance to sirolimus-related toxicity was diminished. Beside the disappointingly poor therapeutic outcome, only subtle effects of sirolimus on mTOR-specific S6K phosphorylation were seen in kidney and liver. In principle, several reasons for the missing efficacy of sirolimus to delay progression of liver and kidney disease in PCK rats have to be considered. First of all, one might argue that either the mode of therapy was inadequate and/ or the dosages were inappropriately low. As has been described previously, sirolimus was administered via the drinking water in order to (i) minimize handling stress for the animals, as from our point of view, daily intraperitoneal injections for treatment periods of 4 weeks and more are hardly feasible, and (ii) to achieve constant rather than fluctuating drug levels [21] . The blood concentrations of sirolimus achieved within the present study were quite comparable not only between PCK and SD rats but also to those reported previously, where the same dosage and mode of administration were used and had shown to be effective in the Han:SPRD rat model of PKD [21] . In contrast, in a recent study on long-term sirolimus treatment in Han:SPRD rats, ∼10-fold higher blood concentrations were achieved by daily intraperitoneal injections [42] . However, this is a different animal model, and although higher effective dosages of sirolimus might have been beneficial with respect to cyst progression in PCK rats, the severe side effects in the present study strongly argue against dose escalation. In fact, a tremendous increase in bilirubin concentration in sirolimus-treated PCK rats together with the unexpected death of five out of 46 treated PCK rats strongly argues against dosage escalation in this model. Instead, these side effects may serve as indicators for a successful drug exposure. Especially, elevated activity of liver enzymes is already listed as the sirolimus-related side effect and induction of acute cholestasis in rats has been described recently [43, 44] . Thus, despite rather low blood levels of sirolimus, a significant hepatic and systemic toxicity has been noted. While beneficial effects from dose escalation are hard to expect, acquired and/or intrinsic resistance to sirolimus might have to be considered as well.
Both the eukaryotic initiation factor 4E binding proteins and S6K (p70 ribosomal S6 kinase) are the key translation regulators downstream of mTOR. Activation of these pathways requires the formation of the mTOR-raptor complex (mTORC1), and the activity of mTORC1 is inhibited by sirolimus [40, 45, 46] . In contrast, mTORC2 consisting of mTOR and rictor is responsible for activation of Akt, and it has been shown only recently that the sirolimus concentration required to inhibit signalling via either complex may differ by several orders of magnitude [47] . Although it is still a matter of discussion whether mTOR activity is directly or indirectly required for activation of S6K, assessing mTOR-specific phosphorylation of S6K has been used to estimate efficacy of sirolimus therapy [21, 42, 48, 49] . However, sirolimus-induced inhibition of mTOR signalling and thus suppression of S6K activity might stimulate activation of Akt secondary to diminished inhibition of insulin-like growth factor receptor signalling [50, 51] . Beyond this, additional interactions between mTORC1-and mTORC2-mediated signalling are likely to exist. Therefore, in the present study, the rather subtle effects on S6K phosphorylation together with strong signals for phosphorylated Akt may reflect alternate routes of activation [52] .
Although resistance to sirolimus is, in general, envisaged as a typical feature of cancer and cancer cell lines, it has been described in non-malignant diseases recently [47, 48, 50, 53, 54] . In fact, long-term exposure of normal murine proximal tubular cells was associated with sirolimus resistance, while with short-term exposure (1 day ver- sus 7 days), a marked suppression of cell proliferation and phosphorylation of S6K was noted [54, 55] . Furthermore, intraperitoneal administration of sirolimus (∼0.2 mg/kg body weight per day) to SD rats with acute renal failure resulted in delay rather than prevention of renal recovery. These findings strongly indicate that healthy tubular cells are able to escape from sirolimus-induced growth arrest, and this feature might be still present in tubular cells of PCK rats. Finally, sirolimus-related transactivation of epidermal growth factor receptor (EGFR)-mediated signalling might be involved as well. Most recently, this phenomenon has been described in non-cancerous rat aortic vascular smooth muscle cells and mouse lung fibroblasts expressing EGFR [50] . Interestingly, the non-receptor tyrosine kinase c-Src was shown to mediate EGFR transactivation in sirolimustreated cells, and over-expression of EGFR has been shown in animal models of ARPKD. Thus, sirolimus might have stimulated aberrant EGFR signalling instead of inducing cell cycle arrest and subsequent attenuation of disease progression [56] .
In summary, despite a sound rationale for considering inhibition of mTOR in the treatment of ARPKD, sirolimus failed to attenuate progression of kidney and liver disease in PCK rats. Whether the lack of protective effect is due to intrinsic or acquired sirolimus resistance in this animal model of ARPKD remains to be elucidated.
